Human Urokinase (uPA) AssayMax ELISA KitHuman Urokinase (uPA) AssayMax ELISA Kit
Move your mouse over image or click to enlarge

Human Urokinase (uPA) AssayMax ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EU1001-1 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Urine, Milk, Cell Culture, Tissue Extract
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 0.125-4 ng/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 5328
Omim 191840
UniProt P00749
UniGene Hs.77274
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Fujiuchi Y et al. (2003) Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol. Rep. 10(4):1001-1006 
* Oka N et al. (2003) Amiloride and Urinary Trypsin Inhibitor Inhibit Urothelial Cancer Invasion. Eur Urol. 44(6):737-741 
* Ueshima S et al. (2003) Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. Pathophysiology 9:103-109 
* Uchima Y et al. (2004) Inhibition and Mechanism of Action of a Protease Inhibitor in Human Pancreatic Cancer Cells. 
* Yamaguchi Y et al. (2004) Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP). Am J Physiol Endocrinol Metab 287(5): E970-E976 
* Nomuraa S et al. (2005) HMG-CoA Reductase Inhibitors Reduce Matrix Metalloproteinase-9 Activity in Human Varicose Veins. 
* Yamaguchi Y et al. (2005) Possible Involvement of Urokinase-Type Plasminogen Activator Release From Human Peripheral Blood Lymphocytes in the Pathophysiology of Chronic Allograft Nephropathy. Transplantation Proceedings. 37(10):4276-4281 
* Cederqvist K et al. (2006) High Concentrations of Plasminogen Activator Inhibitor-1 in Lungs of Preterm Infants With Respiratory Distress Syndrome. Pediatrics 117(4):1226-1234 
* Yang CC et al. (2007) In vitro regulation of adipogenesis: tunable engineered tissues. J Tissue Eng Regen Med. 1(2):146-153 
* Yoshida C et al. (2007) Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. Blood Coagulation & Fibrinolysis. 18(5):425-433 
* Ogura Y et al. (2008) Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction. British Journal of Dermatology 159(1):49-60 
* Ekmekci OB et al. (2009) Effects of rhG-CSF Plus Dexamethasone on Hemostatic Parameters in Healthy Granulocyte Donors: Role of u-PA and Nitric Oxide. Clin. Appl. Thromb. Hemost. 15(6):689-694 
* Okumura S et al. (2009) Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: Preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells. Clin Immunol. 130(2):175-185 
* Grzmil M (2010) An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene. 29(28):4080-4089 
* Rasheed SA et al. (2010) First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 127(6):1475-1485 
* Sutoh T et al. (2010) Nafamostat Mesilate (FUT-175) Inhibits Cell Growth and Invasion of Malignant Pleural Mesothelioma Cell Line, MSTO-211H. Hirosaki Med. J. 61:19-25 
* Ferro M et al. (2012) PLASMATIC SIL 6R/IL-6 RATIO AS A POTENTIAL PREDICTOR OF HIGH GLEASON SUM AT RADICAL PROSTATECTOMY. ANTICANCER RESEARCH 32: 1843-1966 
* Gach K et al. (2012) The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines. Mol Biol (Mosk). 46(6):894-9 
* Wyrebska A et al. (2012) Comparison of Anti-Invasive Activity of Parthenolide and 3-Isopropyl-2-Methyl-4-Methyleneisoxazolidin-5-One (MZ-6) 
* Vieira ML et al. (2013) Interaction of Leptospira interrogans with Human Proteolytic Systems Enhances Dissemination through Endothelial Cells and Protease Levels. Infect Immun. 81(5):1764-74. doi: 10.1128/IAI.00020-13. Epub 2013 Mar 11 
* Mahmoud AE and Ali MM (2014) Fermented Pomegranate (Punica granatum) Peel Extract as a Novel Anticancer Agent Targeting Angiogenesis and Metastasis. International Journal of toxicological and pharmacological research. 6(4):60-66 
* Mori Y et al. (2014) MUC1 Protein Induces Urokinase-type Plasminogen Activator (uPA) by Forming a Complex with NF-?B p65 Transcription Factor and Binding to the uPA Promoter, Leading to Enhanced Invasiveness of Cancer Cells. J Biol Chem. 289(51):35193-35204 
* Rashad MM et al. (2014) Production, characterization and anticancer activity of Candida bombicola sophorolipids by means of solid state fermentation of sunflower oil cake and soybean oil. Grasas Aceites 65 (2), e017. ISSN-L: 0017-3495 
* Rashad AE et al. (2015) Synthesis and anticancer evaluation of some fused pyrazolopyrimidines and their S-acyclic nucleosides. Der Pharma Chemica. 7(5):243-250 

" title="

* Fujiuchi Y et al. (2003) Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol. Rep. 10(4):1001-1006 
* Oka N et al. (2003) Amiloride and Urinary Trypsin Inhibitor Inhibit Urothelial Cancer Invasion. Eur Urol. 44(6):737-741 
* Ueshima S et al. (2003) Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. Pathophysiology 9:103-109 
* Uchima Y et al. (2004) Inhibition and Mechanism of Action of a Protease Inhibitor in Human Pancreatic Cancer Cells. 
* Yamaguchi Y et al. (2004) Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP). Am J Physiol Endocrinol Metab 287(5): E970-E976 
* Nomuraa S et al. (2005) HMG-CoA Reductase Inhibitors Reduce Matrix Metalloproteinase-9 Activity in Human Varicose Veins. 
* Yamaguchi Y et al. (2005) Possible Involvement of Urokinase-Type Plasminogen Activator Release From Human Peripheral Blood Lymphocytes in the Pathophysiology of Chronic Allograft Nephropathy. Transplantation Proceedings. 37(10):4276-4281 
* Cederqvist K et al. (2006) High Concentrations of Plasminogen Activator Inhibitor-1 in Lungs of Preterm Infants With Respiratory Distress Syndrome. Pediatrics 117(4):1226-1234 
* Yang CC et al. (2007) In vitro regulation of adipogenesis: tunable engineered tissues. J Tissue Eng Regen Med. 1(2):146-153 
* Yoshida C et al. (2007) Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. Blood Coagulation & Fibrinolysis. 18(5):425-433 
* Ogura Y et al. (2008) Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction. British Journal of Dermatology 159(1):49-60 
* Ekmekci OB et al. (2009) Effects of rhG-CSF Plus Dexamethasone on Hemostatic Parameters in Healthy Granulocyte Donors: Role of u-PA and Nitric Oxide. Clin. Appl. Thromb. Hemost. 15(6):689-694 
* Okumura S et al. (2009) Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: Preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells. Clin Immunol. 130(2):175-185 
* Grzmil M (2010) An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene. 29(28):4080-4089 
* Rasheed SA et al. (2010) First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 127(6):1475-1485 
* Sutoh T et al. (2010) Nafamostat Mesilate (FUT-175) Inhibits Cell Growth and Invasion of Malignant Pleural Mesothelioma Cell Line, MSTO-211H. Hirosaki Med. J. 61:19-25 
* Ferro M et al. (2012) PLASMATIC SIL 6R/IL-6 RATIO AS A POTENTIAL PREDICTOR OF HIGH GLEASON SUM AT RADICAL PROSTATECTOMY. ANTICANCER RESEARCH 32: 1843-1966 
* Gach K et al. (2012) The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines. Mol Biol (Mosk). 46(6):894-9 
* Wyrebska A et al. (2012) Comparison of Anti-Invasive Activity of Parthenolide and 3-Isopropyl-2-Methyl-4-Methyleneisoxazolidin-5-One (MZ-6) 
* Vieira ML et al. (2013) Interaction of Leptospira interrogans with Human Proteolytic Systems Enhances Dissemination through Endothelial Cells and Protease Levels. Infect Immun. 81(5):1764-74. doi: 10.1128/IAI.00020-13. Epub 2013 Mar 11 
* Mahmoud AE and Ali MM (2014) Fermented Pomegranate (Punica granatum) Peel Extract as a Novel Anticancer Agent Targeting Angiogenesis and Metastasis. International Journal of toxicological and pharmacological research. 6(4):60-66 
* Mori Y et al. (2014) MUC1 Protein Induces Urokinase-type Plasminogen Activator (uPA) by Forming a Complex with NF-?B p65 Transcription Factor and Binding to the uPA Promoter, Leading to Enhanced Invasiveness of Cancer Cells. J Biol Chem. 289(51):35193-35204 
* Rashad MM et al. (2014) Production, characterization and anticancer activity of Candida bombicola sophorolipids by means of solid state fermentation of sunflower oil cake and soybean oil. Grasas Aceites 65 (2), e017. ISSN-L: 0017-3495 
* Rashad AE et al. (2015) Synthesis and anticancer evaluation of some fused pyrazolopyrimidines and their S-acyclic nucleosides. Der Pharma Chemica. 7(5):243-250 

" target="_blank">

* Fujiuchi Y et al. (2003) Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol. Rep. 10(4):1001-1006 
* Oka N et al. (2003) Amiloride and Urinary Trypsin Inhibitor Inhibit Urothelial Cancer Invasion. Eur Urol. 44(6):737-741 
* Ueshima S et al. (2003) Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. Pathophysiology 9:103-109 
* Uchima Y et al. (2004) Inhibition and Mechanism of Action of a Protease Inhibitor in Human Pancreatic Cancer Cells. 
* Yamaguchi Y et al. (2004) Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP). Am J Physiol Endocrinol Metab 287(5): E970-E976 
* Nomuraa S et al. (2005) HMG-CoA Reductase Inhibitors Reduce Matrix Metalloproteinase-9 Activity in Human Varicose Veins. 
* Yamaguchi Y et al. (2005) Possible Involvement of Urokinase-Type Plasminogen Activator Release From Human Peripheral Blood Lymphocytes in the Pathophysiology of Chronic Allograft Nephropathy. Transplantation Proceedings. 37(10):4276-4281 
* Cederqvist K et al. (2006) High Concentrations of Plasminogen Activator Inhibitor-1 in Lungs of Preterm Infants With Respiratory Distress Syndrome. Pediatrics 117(4):1226-1234 
* Yang CC et al. (2007) In vitro regulation of adipogenesis: tunable engineered tissues. J Tissue Eng Regen Med. 1(2):146-153 
* Yoshida C et al. (2007) Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. Blood Coagulation & Fibrinolysis. 18(5):425-433 
* Ogura Y et al. (2008) Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction. British Journal of Dermatology 159(1):49-60 
* Ekmekci OB et al. (2009) Effects of rhG-CSF Plus Dexamethasone on Hemostatic Parameters in Healthy Granulocyte Donors: Role of u-PA and Nitric Oxide. Clin. Appl. Thromb. Hemost. 15(6):689-694 
* Okumura S et al. (2009) Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: Preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells. Clin Immunol. 130(2):175-185 
* Grzmil M (2010) An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene. 29(28):4080-4089 
* Rasheed SA et al. (2010) First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer. 127(6):1475-1485 
* Sutoh T et al. (2010) Nafamostat Mesilate (FUT-175) Inhibits Cell Growth and Invasion of Malignant Pleural Mesothelioma Cell Line, MSTO-211H. Hirosaki Med. J. 61:19-25 
* Ferro M et al. (2012) PLASMATIC SIL 6R/IL-6 RATIO AS A POTENTIAL PREDICTOR OF HIGH GLEASON SUM AT RADICAL PROSTATECTOMY. ANTICANCER RESEARCH 32: 1843-1966 
* Gach K et al. (2012) The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines. Mol Biol (Mosk). 46(6):894-9 
* Wyrebska A et al. (2012) Comparison of Anti-Invasive Activity of Parthenolide and 3-Isopropyl-2-Methyl-4-Methyleneisoxazolidin-5-One (MZ-6) 
* Vieira ML et al. (2013) Interaction of Leptospira interrogans with Human Proteolytic Systems Enhances Dissemination through Endothelial Cells and Protease Levels. Infect Immun. 81(5):1764-74. doi: 10.1128/IAI.00020-13. Epub 2013 Mar 11 
* Mahmoud AE and Ali MM (2014) Fermented Pomegranate (Punica granatum) Peel Extract as a Novel Anticancer Agent Targeting Angiogenesis and Metastasis. International Journal of toxicological and pharmacological research. 6(4):60-66 
* Mori Y et al. (2014) MUC1 Protein Induces Urokinase-type Plasminogen Activator (uPA) by Forming a Complex with NF-?B p65 Transcription Factor and Binding to the uPA Promoter, Leading to Enhanced Invasiveness of Cancer Cells. J Biol Chem. 289(51):35193-35204 
* Rashad MM et al. (2014) Production, characterization and anticancer activity of Candida bombicola sophorolipids by means of solid state fermentation of sunflower oil cake and soybean oil. Grasas Aceites 65 (2), e017. ISSN-L: 0017-3495 
* Rashad AE et al. (2015) Synthesis and anticancer evaluation of some fused pyrazolopyrimidines and their S-acyclic nucleosides. Der Pharma Chemica. 7(5):243-250 

Related Documents